VVD-214 New
Tocris Bioscience, part of Bio-Techne | Catalog # 9027
Potent WRN covalent allosteric inhibitor; orally bioavailable
Key Product Details
Description
Potent WRN covalent allosteric inhibitor; orally bioavailable
Alternative Names
RO7589831
Product Description
VVD-214 is a potent werner syndrome helicase (WRN) covalent allosteric inhibitor (IC50 = 0.13 μM and 2.4 μM with and without ATP, respectively). The selective binding of VVD-214 to cysteine C727 of WRN triggers double-stranded DNA breaks, nuclear swellings, cell death and tumor regression in microsatellite instability-high (MSI-H) colorectal cancer models. Highly stable in hepatocytes and whole blood, VVD-214 is orally bioavailable.Licensing Information
Sold with permission from Vividion TherapeuticsProduct Specifications
Molecular Weight
437.46
Formula
C20H21F2N3O4S
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
N-[(1S,2E)-1-Cyclopropyl-3-(methylsulfonyl)-2-propen-1-yl]-2-(1,1-difluoroethyl)-4-phenoxy-5-pyrimidinecarboxamide
CAS Number
3026500-20-6
PubChem ID
38658751
InChI Key
UWPFUBNCDABUEE-SIFUEBAJSA-N
SMILES
CS(/C=C/[C@H](C1CC1)NC(C(C(OC2=CC=CC=C2)=N3)=CN=C3C(F)(F)C)=O)(=O)=O
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 21.87 | 50 |
Preparing Stock Solutions
for VVD-214
The following data is based on the product molecular weight 437.46
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.57 mL | 22.86 mL | 45.72 mL |
| 2.5 mM | 0.91 mL | 4.57 mL | 9.14 mL |
| 5 mM | 0.46 mL | 2.29 mL | 4.57 mL |
| 25 mM | 0.09 mL | 0.46 mL | 0.91 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Baltgalvis Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature 2024 PMID: 38658751
- Kikuchi Identification of VVD-214/RO7589831, a clinical-stage, covalent allosteric inhibitor of WRN helicase for the treatment of MSI-high cancers. J.Med.Chem. 2025 PMID: 40964743
Product Specific Notices for VVD-214
For research use only
Loading...
Loading...